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Background and Purpose: Asthenozoospermia is a leading cause of male infertility,
but development of pharmacological agents to improve sperm motility is hindered by
the lack of effective screening platforms and knowledge of suitable molecular targets.
We have demonstrated that a high-throughput screening (HTS) strategy and
established in vitro tests can identify and characterise compounds that improve
sperm motility. Here, we applied HTS to identify new compounds from a novel small
molecule library that increase intracellular calcium ([Ca2+]i), promote human sperm
cell motility, and systematically determine the mechanism of action.
Experimental Approach: A validated HTS fluorometric [Ca2+]i assay was used to
screen an in-house library of compounds. Trequinsin hydrochloride (a PDE3 inhibitor)
was selected for detailed molecular (plate reader assays, electrophysiology, and cyclic
nucleotide measurement) and functional (motility and acrosome reaction) testing in
sperm from healthy volunteer donors and, where possible, patients.
Key Results: Fluorometric assays identified trequinsin as an efficacious agonist of
[Ca2+]i, although less potent than progesterone. Functionally, trequinsin significantly
increased cell hyperactivation and penetration into viscous medium in all donor
sperm samples and cell hyperactivation in 22/25 (88%) patient sperm samples.
Trequinsin-induced [Ca2+]i responses were cross-desensitised consistently by PGE1
but not progesterone. Whole-cell patch clamp electrophysiology confirmed that
trequinsin activated CatSper and partly inhibited potassium channel activity.
Trequinsin also increased intracellular cGMP.
Conclusion and Implications: Trequinsin exhibits a novel pharmacological profile in
human sperm and may be a suitable lead compound for the development of new
agents to improve patient sperm function and fertilisation potential.
Abbreviations: [Ca2+]i, intracellular calcium; ACU, Assisted Conception Unit; CASA, computer-assisted sperm analysis; CM, capacitating media; DGC, density gradient centrifugation; Gm,
membrane conductance; HA, hyperactivated motility; HTS, high-throughput screening; ICSI, intracytoplasmic sperm injection; NCM, non-capacitating media; PDE3i, PDE3 inhibitor; PM,
progressive motility; pHi, intracellular pH; sEBSS, supplemented Earls buffered salt solution; TM, total motility; VCL, curvilinear velocity.
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1 | INTRODUCTION
Asthenozoospermia (low sperm motility) has been reported as the
leading cause of male infertility (Kumar & Singh, 2015).
Intracytoplasmic sperm injection (ICSI) is the most common and suc-
cessful treatment for male infertility. While it is a pragmatic solution,
it involves invasive treatment of the female partner and bypasses all
natural sperm selection processes. There are concerns that ICSI may
be associated with long-term health issues for the children born, par-
ticularly in cases where the spermatozoa are predominately immotile
and do not have the capacity to fertilise under natural conditions
(Esteves, Roque, Bedoschi, Haahr, & Humaidan, 2018; Hanevik, Hes-
sen, Sunde, & Breivik, 2016). Therefore, the development of novel
direct treatments for male infertility is desirable, although this repre-
sents a significant challenge because of the limited understanding of
the regulation of normal and dysfunctional sperm (Barratt et al.,
2017).
Intracellular calcium concentration ([Ca2+]i) is an established regu-
lator of sperm function, and a wealth of evidence suggests that the
principal cation channel in sperm (CatSper) influences sperm function
and fertilisation potential through regulation of extracellular calcium
influx (Singh & Rajender, 2015; Strünker et al., 2011; Tamburrino
et al., 2014; Williams et al., 2015). CatSper is confined to the principal
piece of the flagellum and is modulated by intracellular pH (pHi) and
membrane potential. It is sensitive to progesterone (Lishko, Bot-
chkina, & Kirichok, 2011; Strünker et al., 2011), which stimulates cell
penetration into a viscous medium (used as an in vitro model for
regions of the female reproductive tract; Alasmari et al., 2013; Bar-
ratt & Publicover, 2012). [Ca2+]i also plays a significant role in the reg-
ulation of soluble cyclases that drive the production of cyclic
nucleotides. These key secondary messengers have been shown to be
fundamental for human sperm cell motility, cell capacitation, and acro-
some reaction. Cyclic nucleotides are actively enzymatically degraded
by PDEs, and PDE inhibitors can positively affect sperm cell motility
and function (Maréchal et al., 2017; Tardif et al., 2014; Willipinski-
Stapelfeldt et al., 2004).
Identifying CatSper agonists to improve sperm motility and func-
tion is a logical approach to drug discovery for male infertility. We
have previously described the development of a high-throughput
screening (HTS) system to identify compounds that increase [Ca2+]i
and thereafter have assessed the functional consequence of in vitro
application of two compounds (Martins da Silva et al., 2017). How-
ever, sperm motility is multiform and adaptive, and not every patient
sample responded to treatment in vitro. As such, there remains a clear
need to continue to identify potential therapeutic compounds.
In this study, we hypothesised that novel CatSper agonists could
be identified by screening a library of small molecules with defined
molecular targets (chemogenomic library). This library was assembled
from well-characterised, commercially available ligands (Tocris) for a
range of validated drug targets including enzymes, receptors, and
transporters. We demonstrate that trequinsin hydrochloride, a PDE3
inhibitor (PDE3i; Degerman, Belfrage, & Manganiello, 1997; Lal, Doha-
dwalla, Dadkar, D'Sa, & de Souza, 1984), is highly effective at inducing
What is already known
• There is an unmet clinical need for compounds to treat
asthenozoospermia (poor sperm motility).
What this study adds
• Trequinsin hydrochloride raised intracellular calcium and
cyclic GMP in human sperm and improved motility.
What is the clinical significance
• Trequinsin hydrochloride has clinically relevant positive
effects on human sperm motility.
• Thus, trequinsin hydrochloride has the potential to be a
novel treatment for male infertility.
F IGURE 1 Experimental plan. Systematic functional and
mechanistic screening strategy for the identification of the molecular
and functional effects of trequinsin
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an increase in [Ca2+]i, which corresponded with improved sperm
motility. Detailed characterisation of the mechanism of action of
trequinsin suggests that these effects are achieved through complex
and novel pharmacological activities in human spermatozoa.
The study aimed to investigate hit compounds from a
chemogenomic drug library screen for effects on sperm motility and
to determine the mechanism responsible. This was achieved in three
phases. Phase 1 employed HTS of compounds for their ability to
increase sperm [Ca2+]i relative to a saturating concentration of pro-
gesterone (P4). Phase 2 involved detailed sperm function tests, and
Phase 3 involved molecular analysis of trequinsin hydrochloride,
which was selected due to its high efficacy in Phase 1 and its pur-
ported PDE3i activity. An outline of the experimental approach is
shown in Figure 1.
2 | METHODS
2.1 | Ethical approval
Study approval was in accordance with the Human Fertilisation and
Embryology Authority Code of Practice (version 8) and local ethical
approval (13/ES/0091) from East of Scotland Research Ethics Service
REC 1. Following informed consent, samples for research were
obtained from patients undergoing investigation and treatment at the
Assisted Conception Unit (ACU), Ninewells Hospital, Dundee, and that
were surplus to clinical requirement. Samples from healthy volunteer
research donors with normal sperm motility parameters in agreement
with World Health Organization 2010 criteria (Cooper et al., 2010)
were used in this study under the same ethical approval. All obtained
samples for research were analysed in line with suggested guidance
for human semen studies where appropriate (Björndahl, Barratt, Mor-
timer, & Jouannet, 2015).
2.2 | Preparation of donor and patient sperm
samples
All donors and patients adhered to an abstinence period of 2–5
days before sample collection by masturbation into a sterile plastic
container. The sample was placed in a 37C incubator for 30 min
to allow liquefaction. Semen samples from patients were cat-
egorised according to World Health Organization guidelines
(Cooper et al., 2010).
Donor and andrology semen samples were prepared by density
gradient centrifugation (DGC) as described by Martins da Silva et al.
(2017). Solutions for the manufacturing of non-capacitating media
(NCM), capacitating media (CM), and density gradient solutions can be
found in Appendix S1. Preparation of capacitated patient sperm was
carried out by the ACU using commercial media from PureSperm™
(Nidacon, Mölndal, Sweden) and Quinn's Advantage Medium with
HEPES (SAGE In-Vitro Fertilization; Pasadena, CA, USA; Brown et al.,
2016).
2.3 | Chemogenomics library high-throughput
screen
Dundee University Drug Discovery Unit in-house chemogenomics
library was screened for compounds that increase [Ca2+]i in human
sperm. The compound library is composed of a set of 223 commer-
cially available small molecules and drugs (Tocris), each with a well-
defined mechanism of action, potency at the primary target, and
selectivity. The compounds were selected as representative ligands
for a diverse range of drug targets including enzymes, GPCRs, ion
channels, and transporters. The compound library was initially
screened on a single 384 well assay plate, at a single concentration of
40 μM. HTS and data analysis were performed as previously described
(Martins da Silva et al., 2017). In brief, spermatozoa from two to four
different donors were pooled together after preparation by DGC,
diluted to a density of 2.2 × 107·ml−1 in Flexstation assay buffer (1 X
HBSS [Invitrogen], 20-mM HEPES, 0.5-mM probenecid, pH 7.4), and
incubated for 60 min (37C) with 2 x Calcium 3 dye (Molecular
Devices). Spermatozoa were washed following incubation,
resuspended in Flexstation assay buffer, and plated in 384 well clear
bottom, black well assay plates (Greiner Bio One) at a density of 2.5 ×
105 cells/50 μl per well. [Ca2+]i was measured using a Flexstation
3 (Molecular Devices). Baseline calcium-dependent fluorescence (exci-
tation wavelength = 485 nm, emission wavelength = 525 nm, and cut-
off = 515 nm) was measured for 18 s; 12.5 μl of each test compound
was transferred to the assay plate using an internal 16-channel
robotic pipette head, and the resulting change in fluorescence was
monitored for a further 82 s. Follow-up assays were performed to
determine the potency of hit compounds. All assay plates in the
screen were subject to quality control analysis.
Preliminary analysis of all HTS primary and potency raw data was
performed using the AUC function within the SoftMax Pro analysis
software (SoftMax Pro Data Acquisition and Analysis Software, RRID:
SCR_014240) to quantitate agonist-evoked fluorescence as previously
described. Data were exported as a text file for further data
processing and analysis in Activity Base version 7.3.1.4 (IDBS), and the
percentage effect for each compound was normalised to the paired
positive control (10-μM P4). Compounds were pragmatically classified
on the basis of calcium fluorescence elicited and designated as low
responder (blue 20–49%), mild responder (orange 50–89%), and high
responder (green 90–120%) relative to progesterone (Table 1).
2.4 | Motility assessment: Computer-assisted
semen analysis
Prepared spermatozoa were incubated for 3 hr at 37C in CM or
NCM as appropriate and then mixed with DMSO (vehicle control, 1%
final concentration) or trequinsin (10-μM final concentration; Tocris
Bioscience, Abingdon, UK). Sperm cells were incubated for 20 min;
then motility was assessed (using four-chamber 20-μM deep slides;
Vitrolife, Sweden). At least 200 sperm cells were analysed per cham-
ber per condition for each motility parameter (Tardif et al., 2014).
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Motility readings were recorded over a 2-hr period (0, 20, 40, 60,
90, and 120 min) for donor and patient samples using computer-
assisted sperm analysis (CASA; CEROS machine [version 12], Hamil-
ton Thorne Research, Beverly, MA, USA). Parameters measured
included progressive motility (PM), total motility (TM), and hyper-
activated motility (HA). Proprietary algorithms on the CASA deter-
mined the percentage of cells displaying HA automatically.
Specifically, a subpopulation sperm displaying curvilinear velocity
(VCL) ≥150 μm·s−1, linearity <50%, and amplitude of lateral head dis-
placement ≥7 μm of algorithms were designated as hyperactive
(Mortimer & Mortimer, 2013).
2.5 | Motility assessment: Sperm penetration test
Sperm penetration test was conducted using Kremer tubes (0.4 ×
4 mm of internal diameter; CM Scientific Ltd, New Jersey, USA)
placed into Eppendorf tubes containing approximately 1 × 105 sper-
matozoa in CM at 37C, 5% CO2 for 1 hr (Martins da Silva et al.,
2017). The number of spermatozoa was counted manually at 1 and
2 cm and compared between control (1% DMSO), 10-μM trequinsin,
3.6-μM progesterone, and 500-μM IBMX, a non-specific agonist for
sperm motility used as a PDEi positive control (Strünker et al., 2011).
Data were normalised to paired controls and expressed as a
TABLE 1 Summary of [Ca2+]i elevating compounds identified in screen of the chemogenomics library
Compound name Primary action (Tocris)
Percentage increase in fluorescence in
sperm
Zaprinast PDE5/6/9/11 inhibitor 23
SB 218078 Inhibitor of checkpoint kinase 1 (Chk1) 25
RO-3 Selective P2X3 and P2X2/3 antagonist 26
GP 1a Highly selective CB2 receptor agonist 32
NNC 55-0396 dihydrochloride Highly selective Ca2+ channel blocker
(T-type)
32
EHT 1864 Potent inhibitor of Rac family GTPases 32
SD 208 Potent ATP-competitive TGFRI inhibitor 34
SANT-2 Inhibitor of hedgehog (Hh) signalling;
antagonises smoothened activity
36
Repaglinide KATP channel blocker 38
EO 1428 Selective inhibitor of p38α and p38 α2 39
BI 78D3 Selective, competitive JNK inhibitor 45
IKK 16 Selective inhibitor of IKK 47
BRL 50481 Selective PDE7 inhibitor 49
Calcipotriol Vitamin D3 analog 51
AS 1949490 SH2 domain-containing inositol
50-phosphatase 2 (SHIP2) inhibitor
54
U 89843A Positive allosteric modulator of GABAA
receptors
57
SANT-1 Inhibitor of hedgehog (Hh) signalling;
antagonises smoothened activity
57
Ciglitazone Selective PPAR agonist 64
UK 78282 hydrochloride Blocker of KV1.3 and KV1.4 channels 66
GW 9508 Potent and selective FFA1 (GPR40) agonist 67
FPL 64176 Potent activator of Ca2+ channels (L-type) 75
NVP 231 Potent, selective, and reversible CerK
inhibitor
77
Y 29794 oxalate Prolyl endopeptidase inhibitor 88
Trequinsin hydrochloride Ultrapotent inhibitor of PDE3 91
Lylamine hydrochloride CB1 receptor agonist 108
PHA 665752 Potent and selective MET inhibitor 111
JX 401 Potent, reversible p38α inhibitor 115
Note. Twenty-seven U.S. Food and Drug Administration-approved active compounds were identified from the DDU Chemogenomics library screen
following Flexstation assay testing, and categorised based on their ability to increase [Ca2+]i (low to high percentage increase relative to 10-μM
progesterone [positive control]). Trequinsin hydrochloride was selected for this study as it was highly efficacious and a PDE inhibitor (the compound library
screen of all 223 commercially available small molecules and drugs [Ca2+]i is shown in Figure S12).
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penetration index, that is, number of spermatozoa observed with
treatment/number of spermatozoa without treatment (control; Ivic
et al., 2002; Martins da Silva et al., 2017).
2.6 | Flow cytometry analysis
Following 3-hr incubation in capacitating conditions, two aliquots con-
taining 2 × 10−6 sperm were centrifuged at 0.3 x g for 5 min. The
supernatant was removed, and the pellets were resuspended in a
staining solution containing (final concentrations): 10 μg·ml−1 of Alexa
Fluor™ 647 conjugated peanut agglutinin (PNA-647, Life Technolo-
gies Ltd, Paisley, UK) and 0.8 μg·ml−1 of propidium iodide (Life Tech-
nologies Ltd) in supplemented Earls buffered salt solution (sEBSS).
Control-treated (1% DMSO) and trequinsin-treated (10 μM) sperm
were incubated at 37C/5% CO2 for 20 min prior to flow cytometry
analysis. Paired positive controls were conducted within each experi-
ment using control cells treated with the calcium ionophore A21387
(10 μM) and Triton X-100 (0.1%) to induce the acrosome reaction and
cell membrane damage, respectively.
The effect of trequinsin on acrosome reaction and membrane
integrity was assessed using an Intellicyt iQue Screener equipped with
a 488-nm laser. In accordance with Intellicyt guidelines, emission of
fluorescence was detected using fluorescence detector 3 (670-nm LP
filter) and 4 (675/25 nm) for propidium iodide and PNA-647, respec-
tively. Forward scatter and side scatter fluorescence data were
recorded from a minimum of 10,000 events per condition. Threshold
levels were selected to exclude cellular debris, and the gates to dis-
criminate between live/dead and acrosome-reacted/non-reacted
were set using the positive control samples. Data were analysed using
Intellicyt's proprietary Forecyt software.
2.7 | [Ca2+]i fluorescence measurements
After incubation for 3 hr in CM or NCM, approximately 3 × 10−6 per
ml−1 of spermatozoa were incubated with 4.5 μM of FLUO-4 AM,
(Thermo Fisher Scientific, Oregon, USA) for 20 min at 37C, 5% CO2
before centrifugation at 500 g for 3 min. The supernatant was
removed, and the pellet was resuspended in sEBSS (Supporting
Information). Fluorescence measurements were carried out on a
FLUOstar Omega reader (BMG Labtech, Offenburg, Germany) at
37C; 3 × 105 cells were imaged per well (Martins da Silva et al.,
2017; Tardif et al., 2014). To construct the trequinsin dose–response
curve, the trequinsin data were normalised to paired [Ca2+]i response
evoked by 3.4-μM progesterone (to control for unwanted sources of
variation).
Desensitisation experiments were carried in accordance with an
established methodology (Brenker et al., 2018; Schaefer, Hofmann,
Schultz, & Gudermann, 1998; Strünker et al., 2011). The first com-
pound addition was added after 1-min recording of baseline fluores-
cence, followed by addition of the second compound after 5 min.
Control experiments were conducted to demonstrate that
progesterone and PGE1 do not cross-desensitise. Control experiments
to demonstrate desensitisation, involved either addition of progester-
one followed by 17α-hydroxyprogesterone or addition of PGE1
followed by PGE2. The protocol used to assess the mode of action of
trequinsin was similar. Cells were first challenged with either proges-
terone or PGE1 followed, after 5 min, by trequinsin. Readings from an
additional time control well (baseline) were taken as were readings
from a well that was exposed to a single agonist at the time point that
matched the time point of addition of the second agonist in the
desensitisation experiments. All compounds were used at a final con-
centration of 10 μM.
2.8 | Measurement of pHi
After 3 hr in CM, spermatozoa (4 × 10−6 per ml−1) were incubated
with 2-μM 20 ,70-bis(2-carboxyethyl)-5,6-carboxyfluorescein
(ThermoFisher, Paisley, UK) for 30 min at 37C. The cells were cen-
trifuged for 3 min at 500 x g, the supernatant was removed, and the
cells were then resuspended in sEBSS. A FLUOstar Omega reader
(BMG Labtech) was used to detect the emitted fluorescence (excita-
tion wavelength ratio of 440/490 nm and emission wavelength of
530 nm). Cell calibration was achieved following cell lysis by the addi-
tion of 1% Triton X-100, a reading was taken from each well, and a
calibration curve was constructed using 1-M HCl and 1-M NaOH.
Fluorescence measurements for control (cells +1% DMSO) and
trequinsin (10 μM) were recorded, as well as ammonium chloride
(NH4Cl), which was used as a positive control (10-mM final
concentration).
2.9 | Electrophysiology
The effect of trequinsin on individual sperm plasma membrane ion
channels was investigated using whole-cell patch clamp electrophysi-
ology (Brown et al., 2016). Sperm were allowed to settle on a glass
coverslip prior to being placed in the recording chamber that was per-
fused with standard extracellular solution (Supplementary Solutions in
the Supporting Information). Gigaseals were achieved between sperm
midpiece and high resistance (8–12 MΩ) borosilicate glass pipettes
filled with either quasi-physiological standard intracellular solution or
Cs+-based divalent-free intracellular solution to study membrane
slope conductance (Gm) that is predominantly carried by K+ ions
(Brown et al., 2016) and CatSper channels, respectively (Supporting
Information). Transition to whole-cell configuration was achieved by
applying brief suction. To study outward membrane conductance, a
depolarising ramp protocol was imposed (−92 to 68 mV) over 2,500
ms, and membrane potential was held at −92 mV between test pulses.
The effect of trequinsin on reversal potential and membrane slope
conductance of outward currents was assessed by regression analysis
over the voltage range where membrane current crosses the x axis (I =
0) and outward current from 20 to 68 mV, respectively (Brown et al.,
2016).
MCBRINN ET AL. 4525
After achieving the whole-cell configuration, monovalent CatSper
currents were recorded by superfusing sperm with Cs+-based
divalent-free bath solution (Supplementary Solutions in the
Supporting Information). Currents were evoked by a ramp protocol
(−80 to 80 mV over 1 s). Membrane potential was held at 0 mV
between ramps. Data were sampled at 2 kHz and filtered at 1 kHz
(PClamp 10 software, Axon Instruments, USA). The post-recording
analysis was conducted as described previously to adjust for liquid
junction potential and normalise for cell size (Brown et al., 2016).
2.10 | Detection of cyclic nucleotides by reversed-
phase HPLC
2.10.1 | HPLC sample preparation
After 3-hr incubation in CM, 9 × 10−6 per ml−1 of spermatozoa were
treated with 1% DMSO (vehicle control), 10-μM trequinsin, or
500-μM IBMX (positive control) and incubated for a further 20 min.
The samples were centrifuged (5 min, 300 x g), the supernatant was
removed, and the pellet was resuspended in 0.5 ml of 100-mM
sodium acetate (pH 4), sonicated for 1 min in a water bath, briefly
vortexed, and centrifuged again (5 min, 3,000 g). The supernatant was
removed and placed in a fresh Eppendorf, snap frozen in liquid nitro-
gen, and stored on dry ice until solid phase extraction.
2.10.2 | Solid phase extraction
Cyclic nucleotides were extracted using Strata™-X-AW (Phenomenex,
Cheshire, UK) 33-μM polymeric weak anion solid phase extraction
cartridges. Cartridges were pretreated with 1:1 of 100-mM sodium
acetate and water (final pH 4), conditioned with 0.5 ml 100% metha-
nol, and equilibrated with 0.5 ml of 100-mM sodium acetate (final pH
4). The supernatant was then loaded into the cartridge, washed with
0.5 ml of sodium acetate (final pH 4), followed by 0.5 ml of 100%
methanol, and dried for 5 min under full vacuum before 0.5 ml of
28–30% (w/v) solution of ammonium hydroxide was added to metha-
nol (95:5) in order to elute the cyclic nucleotides into ice-cold 1.5-ml
centrifuge tubes. This solution was dried under nitrogen for 30 min
and suspended in 0.5 ml of mobile phase (20-mM potassium phos-
phate in 100% ultrapure water, 0.1% TFA, and 0.1% ACN, pH 2.8
adjusted with 2.5% phosphoric acid).
2.10.3 | Standards and stock solutions
Stock solutions of cyclic nucleotides (cAMP and cGMP) were pre-
pared to 3 mol·L−1 in mobile phase (see Section 2.10.4). From the
stock solutions, five 10-fold serial dilutions were produced to achieve
a 6-point standard curve (peak AUC). This was used for quantification
of cyclic nucleotides in sperm samples.
2.10.4 | HPLC set-up
The HPLC system comprised Waters 1525 binary HPLC pump, 2487
dual λ absorbance detector, 717 plus autosampler, and a Synergi™
4-μm fusion—RP80A (Phenomenex, Cheshire, UK) C18 analytical col-
umn (150 mm × 4.6 mm of internal diameter, 4-μm particle size).
Mobile phase: Isocratic elution of 100% 20-mM potassium phosphate
in ultrapure, filtered and degassed water, with 0.1% TFA and 0.1
ACN, pH 2.8 with 2.5% phosphoric acid. Chromatographic conditions:
Flow rate: 1 ml·min−1. Injection volume: 200 μl. Detection wave-
lengths: 255 nm (cGMP) and 256 nm (cAMP).
2.11 | Data and statistical analysis
The data and statistical analysis comply with the recommendations on
experimental design and analysis in pharmacology (Curtis et al., 2018).
This research did not include the use of animals. Statistical power
analysis was conducted to ensure that the group size was sufficient to
measure an effect for each experiment using R pwr package (R
Project for Statistical Computing, RRID:SCR_001905; pwr.2p.test) and
Cohen's effect size analysis (control vs. treatment, sig. level = 0.05,
power = 0.8). N numbers refer to data from independent samples.
Donor samples were allocated randomly by the technical team, and
patient samples were provided by the ACU based on consent and
recruitment on the day of treatment. In cases of analysis of responses
from individual patients, replicates were not possible. Therefore, the
analysis was conducted, as indicated in Section 2.12. Blinding of the
operator and the data analysis were not undertaken. However, several
investigators were used throughout the study to ensure the consis-
tency of observed effects.
A total of 28 donors and 25 patients were included in this study.
Statistical comparisons for the effect of trequinsin versus control con-
ditions used paired t tests, unpaired t tests, or two-way ANOVA and
Sidak's multiple comparison analysis as appropriate using the statisti-
cal package GraphPad Prism 7 (La Jolla, CA, USA; GraphPad Prism,
RRID:SCR_002798) unless stated otherwise. P < .05 as represented
by * is considered significant. [Ca2+]i and pHi studies were recorded
as the percentage change in fluorescence from baseline conditions.
For the analysis of individual patient sperm motility results, statistical
significance was recorded when the ±SD did not overlap for control
and treatment conditions (Tardif et al., 2014). HPLC data were
extracted using Breeze 2 software and analysed using Microsoft
Excel. Results are expressed as pmol per 106 cells.
2.12 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMA-
COLOGY (Harding & Sharman et al., 2018), and are permanently
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archived in the Concise Guide to PHARMACOLOGY 2017/18
(Alexander, Fabbro et al., 2017; Alexander, Striessnig et al., 2017).
3 | RESULTS
3.1 | Phase 1: Drug library screen
Dundee University Drug Discovery Unit chemogenomic library com-
pounds were screened for their ability to evoke an increase in [Ca2+]i
in capacitated sperm relative to a saturating dose of progesterone (3.6
μM) using a fluorometric HTS assay and Flexstation 3 microplate
reader. When tested at a single concentration of 40 μM, we identified
27 putative hits eliciting >23% effect (12.1% hit rate), 23 putative hits
with >50% effect (10.3% hit rate), and four putative hits with >90%
effect (1.8% hit rate; Table 1). Trequinsin hydrochloride was notable
among the compounds eliciting the greatest increase in [Ca2+]i, as it is
a PDE enzyme inhibitor (PDEi) and we have previously shown that
similar compounds provide clinically relevant enhancement of sperm
motility (Tardif et al., 2014). Trequinsin caused a concentration-
dependent increase in [Ca2+]i (EC50 = 6.4 μM [95% confidence interval
(CI): 4.1–9.9 μM]; Figure S1). The functional and molecular profile of
trequinsin was studied in further detail, as presented in this report.
The other three compounds eliciting >90% increase in [Ca2+]i did not
promote motility (as assessed by CASA, data not shown) and were
therefore not studied further.
3.2 | Phase 2: Functional effects of trequinsin
3.2.1 | Donor sperm assessment
It is well accepted that activation of CatSper and elevation of cyclic
nucleotides are fundamental for sperm motility and function (Ahmad
et al., 2015; Alasmari, Costello, et al., 2013; Lefièvre, de Lamirande, &
Gagnon, 2002). Motility and kinematic parameters of capacitated
spermatozoa from healthy volunteer donors (80% DGC fraction) after
20-min exposure to trequinsin were studied using CASA. Trequinsin
(0.1–100 μM) had no significant effect on TM or PM (Figure S2).
However, a bell-shaped dose–response curve was obtained for HA (-
Figure S2). As ≥30 μM had no effect on HA, 10-μM trequinsin was
used in subsequent experiments. Capacitated sperm from the 80%
DGC fraction exposed to 10-μM trequinsin showed no change in TM
or PM (Figure S3A,B) over a 2-hr period. However, the percentage of
HA cells sperm was significantly increased (Figure 2). We also
assessed the ability of trequinsin to stimulate penetration into viscous
medium (Kremer test) as a measure of functional motility in the same
spermatozoa population (80%, capacitated). Trequinsin, progesterone,
and IBMX all significantly and similarly increased cell penetration into
viscous medium at 1 cm. However, trequinsin and progesterone were
significantly better than IBMX at stimulating penetration at 2 cm
(Figure 3). Trequinsin did not induce premature acrosome reaction in
capacitated cells (Figure S4B). In contrast, trequinsin had no effect on
the motility parameters of cells from the 80% fraction in non-
capacitating conditions (Figure S5A–C).
Cells with poor motility isolated from 40% fraction after DGC
preparation of ejaculates from healthy volunteer sperm donors were
initially used as a surrogate for patient sperm, as previously described
(Tardif et al., 2014). In contrast to donor 80% fraction cells incubated
in capacitating conditions, 40% fraction capacitated cells showed a
trequinsin-induced significant increase in PM 40 min after initial expo-
sure, which was maintained for the duration of the assay period
F IGURE 2 Effect of trequinsin on capacitated donor sperm cell
hyperactivation. Trequinsin significantly increased HA in all donor
cells from the 80% DGC fraction exposed to capacitating conditions.
*P<.05, significantly different from start (time 0); two-way ANOVA
with Sidak's multiple comparison analysis. The increase in
hyperactivation was sustained for a 2-hr period after initial exposure.
A minimum of 200 cells were counted at each time point.
Hyperactivation classified by CASA parameters: VCL >150 μM·s−1,
linearity <50%, and amplitude of lateral head displacement >7 μM. In
the same sample set, %TM and %PM were unaffected by the addition
of trequinsin (Figure S3)
F IGURE 3 Sperm penetration assay. The ability of trequinsin to
stimulate sperm penetration into viscous medium was assessed using
capacitated sperm from the 80% DGC fraction (n = 5). A significant
increase in cell penetration was observed in the presence of
trequinsin in comparison to control, but not in comparison to cells
stimulated with progesterone (P4). Cell penetration at 1 cm was not
significantly different between trequinsin- and IBMX-treated cells.
However, trequinsin stimulated a significantly greater cell number to
penetrate at 2 cm compared to IBMX. *P<.05, significantly different
from control; two-way ANOVA with Sidak's multiple comparison
analysis
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(Figure 4a). Although there was no effect on TM (Figure S6A), hyper-
activation was also significantly increased, similar to donor 80% frac-
tion cells (Figure 4b). Under non-capacitating conditions, trequinsin
significantly improved PM of 40% fraction sperm for the entire experi-
mental period (Figure 4c) but had no effect on TM or hyperactivation
(Figure S6B,C). The significant changes in motility seen in sperm from
the 40% DGC fraction in capacitating conditions provided proof of
concept that trequinsin may similarly boost sperm motility in poorly
motile sperm from patients. To investigate this further, we assessed
patient sperm motility over a 2-hr period in response to treatment
with trequinsin exposed to capacitating conditions.
3.2.2 | Patient sperm assessment
A total of 25 patients attending the ACU for routine andrology assess-
ment, in vitro fertilisation, ICSI, and sperm study patients (Table 2)
TABLE 2 Effect of trequinsin on patient sperm motility
Patient
ID
Initial WHO semen criteria
assessment
Effect of trequinsin
on patient sperm
motility
Conc.
(M·ml−1)
PM
(%) Classification
TM
(%)
PM
(%)
HA
(%)
R2117 ✓ ✓ Normal # # #
R2926 ✓ ✓ Normal — — "
R2929 ✓ ✓ Normal — — "
R2937 ✓ ✓ Normal — # "
R2939 ✓ ✓ Normal — — "
R2945 ✓ ✓ Normal — # "
R2946 ✓ ✓ Normal — — —
R2947 ✓ ✓ Normal — — —
R2949 ✓ ✓ Normal " " "
R2951 ✓ ✓ Normal — — "
R2952 ✓ ✓ Normal — — "
R2919 ✓ ✓ Normal — — "
R2927 ✓ × Borderline " — "
R2792 ✓ × Borderline — — "
R2931 ✓ × Borderline # — "
R2935 ✓ × Borderline — — "
R2943 × ✓ Borderline — — "
R2950 ✓ × Borderline " " "
R2953 ✓ × Borderline — — "
R2971 ✓ × Borderline — — "
R2974 ✓ × Borderline — — "
R2976 × × Low " " "
R2340 × × Low — — "
R2730 × × Low " " "
R2938 × × Low — — "
Note. Summary of motility changes in patient samples (in vitro fertilisation,
ICSI, and andrology) treated with 10-μM trequinsin. The motility of 25
patient samples was assessed using CASA over a 2-hr period at regular
intervals (see Section 2), and an average for each parameter was taken
overall. A minimum of 200 cells were counted at each time point. ",
significant increase; —, no change; #, significant decrease. Significant
means and SD (control vs. treatment at each time point) do not or do
overlap for increase and decrease, respectively (TM, total motility; PM,
progressive motility; HA, hyperactivated motility). Patient samples are
categorised based on semen World Health Organization (WHO)
parameters (see Section 2). ✓ represents a WHO guideline criterion met; ×
represents a criterion not meeting WHO guidelines.
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F IGURE 4 Effect of trequinsin on 40% DGC fraction (poor
motility) donor sperm motility. Trequinsin significantly increased the
percentage of progressively motile sperm in (a) capacitating (n = 5)
and (b) non-capacitating (n = 6) conditions. Hyperactivation was also
significantly increased when sperm were incubated in (c) capacitating
conditions (n = 8). *P<.05, significantly different compared to time 0;
two-way ANOVA with Sidak's multiple comparison analysis.
Corresponding motility data can be found in Figure S6
added on 27 December 2019, after first online publication: Figure 4
parts  B and C have been relabelled. ]
[Corrections
consented to provide their sample for research. Trequinsin increased
the percentage of hyperactivated cells in the majority (88%) of capaci-
tated patient sperm samples (22/25). TM and PM were unaffected by
treatment with trequinsin in the majority of samples (18/25 for TM
and 18/25 samples for PM). Of note, trequinsin did not alter motility
parameters in two samples (R2946 and R2947) and negatively
affected all motility parameters in only one sample (R2117).
3.3 | Phase 3: Molecular actions of trequinsin
Elevated hyperactivation was the most consistent effect induced by
trequinsin. Therefore, we subsequently explored the molecular actions
of sperm incubated in capacitating conditions. We first analysed the
trequinsin-induced [Ca2+]i increase from capacitated donor cell
populations (80% DGC) normalised to a saturating concentration of
progesterone (3.6 μM; to control for unwanted sources of variation).
Trequinsin induced a concentration-dependent increase in [Ca2+]i
(trequinsin-induced peak EC50 = 3.43 μM [95% confidence limit:
2.19–5.82 μM]; Figure 5a,b), with an agonist profile analogous to pro-
gesterone. Interestingly, although the potency of progesterone is
reported to be higher (progesterone peak = EC50 33 nM; Strünker
et al., 2011), the efficacy of 10-μM trequinsin was equivalent to pro-
gesterone (Figure 5c).
CatSper is a ligand-activated, pHi and voltage-sensitive channel.
Therefore, to investigate the mechanism by which trequinsin causes
an increase in [Ca2+]i, we utilised whole-cell patch clamp electrophysi-
ology to examine the drug's ability to modulate ion channel function
directly and monitored changes in pHi using the ratiometric dye 20,70-
bis(2-carboxyethyl)-5,6-carboxyfluorescein. Predictably, trequinsin
significantly potentiated inward and outward CatSper currents, to a
degree not significantly different from progesterone (Figure 6a,b).
However, trequinsin also had inhibitory activity on potassium channel
function as 10-μM trequinsin also significantly suppressed the mem-
brane slope conductance of outward current (Figure 6e,f) causing a
significant shift in reversal potential (control = −29.7 ± 6.6 mV,
+10-μM trequinsin = −17.4 ± 6.7 mV, Figure 6e). Trequinsin had no
direct effect on pHi (Figure S7). PGE1 and progesterone activate Cat-
Sper through mechanisms that exhibit limited cross-desensitisation
(Brenker et al., 2018; Lishko et al., 2011; Miller et al., 2016a, 2016b;
Schaefer et al., 1998; Shimizu et al., 1998; Strünker et al., 2011).
Therefore, we exploited this phenomenon to investigate the mecha-
nism of the trequinsin-induced increase in [Ca2+]i. Pretreatment with
progesterone caused desensitisation of the response to 17-OH-
progesterone but not PGE1 or trequinsin (Figure 7). Fittingly, pre-
treatment with PGE1 caused desensitisation of the trequinsin, but not
the progesterone response (Figure 7). Trequinsin is a potent PDE3i
(Tinsley et al., 2009). PDE enzymes control the hydrolysis of cyclic
nucleotides, specifically cAMP and cGMP, both of which are sub-
strates for PDE3 (Lefièvre et al., 2002). In contrast to the non-specific
PDEi IBMX, trequinsin did not significantly induce elevation of cAMP
(Figure 8a). However, it induced a significant ~4-fold increase of
cGMP in capacitated cells (Figure 8b).
3.3.1 | Patient [Ca2+]i profile in response to
trequinsin
Given that poor motility and impaired fertilisation potential are associ-
ated with impaired CatSper function (Kelly et al., 2018), it is important
F IGURE 5 Effect of trequinsin on [Ca2+]i in capacitated donor
cells. (a) Mean dose response traces for trequinsin (0.1–30 μM).
(b) Dose–response curve for trequinsin induced peak of [Ca2+]i
relative to progesterone (3.6 μM; EC50 = 3.43 μM [95% confidence
limit: 2.19–5.82 μM]; n = 5) in 80% DGC fraction capacitated donor
sperm. (c) Mean data set (n = 6) trace of 10-μM trequinsin and 3.6-μM
progesterone [Ca2+]i recording (# represents the addition of
compounds, O highlights the peak, and П represents the sustained
[between 180 and 200 s] fluorescent measured). Peak and sustained
responses for progesterone and trequinsin are not significantly
different
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to determine, where feasible, the functionality of CatSper in patient
sperm. Sufficient spermatozoa were available in 9/25 patient samples
to examine the ability of trequinsin to increase [Ca2+]i; 10-μM
trequinsin increased [Ca2+]i as efficaciously as progesterone
(Figure S8), indicating no fundamental abnormality in calcium signal-
ling in these samples. Interestingly, trequinsin did not alter motility
parameters of sperm from patient R2947 despite a robust increase
(>50% ΔF in [Ca2+]i; Figure S10).
F IGURE 6 Patch clamp electrophysiology. (a, b) Inward CatSper-mediated Cs+ currents (n = 6) in response to trequinsin (10 μM) were not
significantly different to progesterone (P4) (c, d). *P<.05, significantly different from control response; two-way ANOVA with Sidak's multiple
comparison analysis. (e) I–V relationship showing the shift in reversal potential and Gm inhibitory effect caused by 10-μM trequinsin (n = 7). (f)
Dose–response curve for showing the partial inhibitory effect of trequinsin on Gm (n = 5). Patch clamp solution configurations are shown in
insets. Donor sperm were from the 80% DGC fraction incubated in capacitating conditions
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4 | DISCUSSION
Male infertility is a significant health challenge that is estimated to
affect one in 10 men (Datta et al., 2016). In up to 40% of these cases,
the cause may be due to reduced sperm motility (asthenozoospermia;
van der Steeg et al., 2011). However, as there are currently no
licensed agents to treat infertile men, ICSI remains the only viable
treatment option to ensure oocyte–spermatozoon interaction. A fun-
damental reason for the shortfall in progression in the field of male
fertility therapeutics has been the lack of knowledge regarding a
F IGURE 7 Examination of agonist cross-desensitisation. Population average [Ca2+]i trace using capacitated donor sperm from the 80% DGC
fraction (n = 5) showing initial agonist addition of either a saturating concentration of 10-μM progesterone (P4) (a, c, e) or 10-μM PGE1 (b, d, f),
followed by the second agonist addition. A baseline control shown in blue was included in each experiment and a blank (sEEBS, represented as
“B”) followed by the addition of the second agonist green. Cross-desensitisation experiments are shown in red. (g) Bar chart showing cell exposed
to 10-μM 17-OH- progesterone (17OHP4) did not produce a significant Ca2+ response compared to that of PGE1 (10 μM) and trequinsin (10 μM).
Effects of PGE1 and trequinsin were not significantly different. *P<.05, significantly different as indicated; two-way ANOVA with Sidak's multiple
comparison analysis. (h) Cells pre-exposed to 10-μM PGE2 had significantly lower Ca2+ responses (<2%) compared to progesterone exposure.
Effects of PGE2 and trequinsin were not significantly different. *P<.05, significantly different as indicated; two-way ANOVA with Sidak's multiple
comparison analysis
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suitable molecular target in sperm, thereby limiting the opportunity
for implementing drug discovery strategies (Barratt, De Jonge, &
Sharpe, 2018; Hughes, Rees, Kalindjian, & Philpott, 2011). However, a
wealth of studies now demonstrate that CatSper is a key determinant
of sperm motility and fertilisation competence (Alasmari, Costello,
et al., 2013; Brown et al., 2018; Kelly et al., 2018; Ren et al., 2001;
Smith et al., 2013; Strünker et al., 2011; Williams et al., 2015) and
therefore represents a plausible target for the development of novel
therapeutics for male infertility. We have previously described a high-
throughput drug screening methodology in conjunction with relevant
in vitro tests to identify compounds that increase functional sperm
motility (Martins da Silva et al., 2017). While this study validated our
drug discovery strategy, there continues to be a significant unmet
clinical need to identify efficacious compounds that influence differ-
ent forms of sperm motility and function. In this study, we utilised an
HTS strategy to screen an in-house drug discovery library and identi-
fied trequinsin hydrochloride, a putative selective PDE3i, which signif-
icantly increased [Ca2+]i.
CatSper is the primary calcium-conducting plasma membrane
ion channel in sperm that is activated by intracellular alkalinisation,
membrane depolarisation, and physiological ligands such as proges-
terone and PGE1 (Singh & Rajender, 2015; Strünker et al., 2011;
Tamburrino et al., 2014). It can also be manipulated by compounds,
including endocrine disrupting chemicals, that may compromise
sperm function (Schiffer et al., 2014; Tavares et al., 2013). Detailed
analysis of the trequinsin-induced [Ca2+]i increase in cell
populations showed that the kinetics of the response mirrored that
of progesterone. However, while whole-cell patch clamp electro-
physiology confirmed the ability of trequinsin to potentiate CatSper
currents to a degree not significantly different from progesterone,
it was also able to suppress outward Gm. Progesterone is proposed
to activate CatSper indirectly through stimulation of a plasma
membrane lipid hydrolase ABHD2 which metabolises endogenous
inhibitory endocannabinoids to cause channel opening. In contrast,
PGE1 activates the channel directly (Miller et al., 2016a, 2016b).
We exploited observations that these mechanisms exhibit limited
cross-desensitisation (Brenker et al., 2018; Lishko et al., 2011;
Miller et al., 2016a, 2016b; Schaefer et al., 1998; Shimizu et al.,
1998; Strünker et al., 2011) to show that the trequinsin cross-
desensitisation profile is indistinguishable from that of PGE1. As
trequinsin did not alter pHi, we conclude that trequinsin increases
[Ca2+]i by a combination of direct activation of CatSper as well as
by membrane potential depolarisation through a partial blocking
effect on the sperm potassium channel. However, we cannot rule
out additional direct actions on pathways that regulate intracellular
stores (Correia, Michelangeli, & Publicover, 2015) or extracellular
calcium entry (De Blas et al., 2009; De Toni et al., 2016; Kumar
et al., 2016).
Trequinsin is a potent (subnanomolar IC50) inhibitor of recombi-
nant PDE3 (Tinsley et al., 2009). As cyclic nucleotides are essential
second messengers for sperm motility (Balbach, Beckert, Hansen, &
Wachten, 2018; Jansen et al., 2015; Mukherjee et al., 2016), we
utilised HPLC to measure cAMP and cGMP changes in sperm exposed
to trequinsin and demonstrated that only cGMP was significantly
increased. Given that PDE3 enzymes metabolise cAMP and cGMP
(Ahmad, Degerman, & Manganiello, 2012), this result is surprising
because pharmacological and immunological evidence supports the
presence of PDE3 in human sperm, localised to the postacrosomal
region of the head (Lefièvre et al., 2002). In contrast, PDE3 isoforms
were not among the seven PDE enzymes identified in a study ana-
lysing the human sperm proteome (Wang et al., 2013). Therefore, our
data may reflect the inhibitory activity of cGMP-PDE, PDE6D. The
notion of non-selective PDE-inhibitory activity of trequinsin is
supported by the relatively high concentration that is required to
increase HA. In fact, 10-μM trequinsin is above the IC50 at the cAMP-
specific PDE2A and PDE4 and cGMP-specific PDE5A (Souness &
F IGURE 8 Measurement of cyclic nucleotide levels in capacitated
80% DGC fraction donor sperm using RP-HPLC. (a) Trequinsin did not
alter intracellular cAMP in comparison to control (cells +1% DMSO; n
= 11). (b) Trequinsin significantly increased intracellular cGMP (n =
11). IBMX, a non-specific PDEi, was used as a positive control. IBMX
significantly increased both cAMP and cGMP (n = 11). *P<.05,
significantly different as indicated; two-way ANOVA with Sidak's
multiple comparison analysis
MCBRINN ET AL.4532
Rao, 1997; Tinsley et al., 2009; Wunder, Gnoth, Geerts, & Barufe,
2009). However, proteomic data do not support their expression in
human sperm (Wang et al., 2013). It is notable that micromolar con-
centrations of PDEi are generally required to induce improvements in
human sperm motility (Alasmari et al., 2013.; Lefièvre et al., 2002;
Maréchal et al., 2017; Tardif et al., 2014) but the reason for this is
unknown.
Given that NO donor compounds can modify sperm kinematic
parameters, including VCL and straight line velocity, it is entirely plau-
sible that an effect of trequinsin on cGMP levels may contribute to
the changes seen in VCL and straight line velocity (Figure S11;
Miraglia et al., 2011). In further support for this mode of action,
trequinsin increased the percentage of sperm exhibiting HA and pene-
tration into viscous medium under capacitating conditions in all donor
samples. Reassuringly, premature acrosome reaction was not induced
in these samples; implying sperm-zona pellucida binding would not be
hindered.
As expected, the increase in hyperactivation was dependent upon
cell capacitation status. Hyperactivation was unaltered in cells
maintained in non-capacitating conditions, despite trequinsin giving a
robust [Ca2+]i increase in these cells (Figure S9). Although trequinsin
was highly effective at increasing hyperactivation in patient sperm
samples incubated in capacitating conditions (22/25), two were unre-
sponsive, and all motility parameters were reduced in one. The reason
for this profile is unknown, but we could demonstrate that one unre-
sponsive case (R2947) was not due to defective [Ca2+]i signalling (-
Figure S10). Biological variability is certainly seen within human sperm
populations. Indeed, not all patients respond to drugs, and this finding
may not be uncommon (Alvarez et al., 2003; Moohan, Winston, &
Lindsay, 1993).
Consequently, the same level of exposure to a drug, for example,
trequinsin, may result in different levels of biological effects in individ-
ual patients. This is the key concept encompassed by the term
“individualised medicine.” Determining the reasons for the biological
variability seen in this and other studies (Martins da Silva et al., 2017)
is an important consideration for future drug development and is
dependent upon robust screening strategies and phenotypic assays to
identify and treat specific molecular and functional impairment. Addi-
tionally, the development of multi-target compounds could be advan-
tageous. For example, it would be interesting to determine if
trequinsin could restore the fertilising potential of sperm affected by
CatSper and sperm potassium channel dysfunction (Brown et al.,
2016; Kelly et al., 2018; Williams et al., 2015).
In summary, we have shown that trequinsin hydrochloride is an
efficacious CatSper agonist that suppresses sperm potassium channel
activity, elevates cGMP (but not cAMP), and induces similar kinetics
of [Ca2+]i increase as progesterone through a mechanism that cross-
desensitises with PGE1 . This novel pharmacological profile results in a
phenotype of increased hyperactivation and penetration into viscous
medium, which is relevant to sperm function required for natural con-
ception. We conclude that the pharmacological profile of trequinsin in
human sperm is unique in terms of effect on multiple key intracellular
mediators that influence sperm function (Esposito et al., 2004; Hess
et al., 2005; Martins da Silva et al., 2017; Tardif et al., 2014; Williams
et al., 2015) and holds promise as a novel agent to treat male
infertility.
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